278 | Humans |
235 | Parkinson Disease |
189 | Male |
177 | Female |
155 | Aged |
150 | Middle Aged |
79 | Animals |
73 | Adult |
50 | Aged, 80 and over |
37 | Antiparkinson Agents |
36 | Levodopa |
30 | Brain |
29 | Treatment Outcome |
27 | Severity of Illness Index |
27 | Dopamine |
27 | Case-Control Studies |
24 | Neurons |
24 | Mice |
23 | United States |
23 | Mutation |
23 | Canada |
22 | Double-Blind Method |
21 | Disease Progression |
20 | Cohort Studies |
19 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
19 | Genetic Predisposition to Disease |
19 | Disease Models, Animal |
19 | Corpus Striatum |
18 | Risk Factors |
18 | Protein-Serine-Threonine Kinases |
18 | Dementia |
16 | alpha-Synuclein |
16 | Retrospective Studies |
16 | Follow-Up Studies |
15 | Time Factors |
15 | Cognition Disorders |
14 | Polymorphism, Single Nucleotide |
14 | Deep Brain Stimulation |
13 | Positron-Emission Tomography |
13 | Neuropsychological Tests |
13 | Genotype |
12 | Tomography, Emission-Computed |
12 | Surveys and Questionnaires |
12 | Rats |
12 | Randomized Controlled Trials as Topic |
12 | Magnetic Resonance Imaging |
12 | Dopamine Agents |
11 | Subthalamic Nucleus |
11 | Substantia Nigra |
11 | Nerve Tissue Proteins |
11 | Motor Activity |
11 | Longitudinal Studies |
11 | Alzheimer Disease |
10 | Psychomotor Performance |
10 | Parkinson Disease, Secondary |
10 | Movement Disorders |
10 | Dyskinesia, Drug-Induced |
10 | Dopamine Plasma Membrane Transport Proteins |
10 | Dopamine Agonists |
10 | Dihydroxyphenylalanine |
10 | Age of Onset |
10 | Adolescent |
9 | Prospective Studies |
9 | Parkinsonian Disorders |
9 | Immunohistochemistry |
9 | Genome-Wide Association Study |
9 | Functional Laterality |
9 | Dose-Response Relationship, Drug |
9 | Dopaminergic Neurons |
9 | Disability Evaluation |
9 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
8 | tau Proteins |
8 | RNA, Messenger |
8 | Quality of Life |
8 | Predictive Value of Tests |
8 | Phenotype |
8 | Pedigree |
8 | Mice, Transgenic |
8 | Mice, Inbred C57BL |
8 | Macaca fascicularis |
8 | Haplotypes |
8 | Gene Frequency |
8 | Cells, Cultured |
8 | Arctic Regions |
7 | Signal Transduction |
7 | Risk Assessment |
7 | Reproducibility of Results |
7 | REM Sleep Behavior Disorder |
7 | Putamen |
7 | Proportional Hazards Models |
7 | Neuroprotective Agents |
7 | Fluorine Radioisotopes |
7 | Drug Therapy, Combination |
7 | Depression |
7 | Databases, Factual |
7 | Cognition |
7 | Cell Survival |
7 | Analysis of Variance |
7 | Age Factors |
7 | Activities of Daily Living |
6 | Supranuclear Palsy, Progressive |
6 | Risk |
6 | Rats, Sprague-Dawley |
6 | Oxidative Stress |
6 | Neurodegenerative Diseases |
6 | Neural Pathways |
6 | Molecular Sequence Data |
6 | Models, Biological |
6 | Mitochondria |
6 | Mesencephalon |
6 | International Cooperation |
6 | Globus Pallidus |
6 | Genetic Association Studies |
6 | Electrodes, Implanted |
6 | Comorbidity |
6 | Brain Mapping |
6 | Biomarkers |
6 | Benzothiazoles |
6 | Amyotrophic Lateral Sclerosis |
6 | Amino Acid Sequence |
5 | Young Adult |
5 | Up-Regulation |
5 | Tyrosine 3-Monooxygenase |
5 | Stroke |
5 | Selegiline |
5 | Reaction Time |
5 | Radiopharmaceuticals |
5 | Psychiatric Status Rating Scales |
5 | Protein Kinases |
5 | Prevalence |
5 | Postural Balance |
5 | Postoperative Complications |
5 | Photic Stimulation |
5 | Outcome Assessment (Health Care) |
5 | Mice, Knockout |
5 | Memory |
5 | Membrane Proteins |
5 | Lewy Body Disease |
5 | Guam |
5 | Genetic Variation |
5 | Gene Expression |
5 | Gene Expression Regulation |
5 | Family Health |
5 | Essential Tremor |
5 | DNA Mutational Analysis |
5 | Clinical Trials as Topic |
5 | Child |
5 | Blotting, Western |
5 | Autopsy |
5 | Action Potentials |
4 | Ubiquitin-Protein Ligases |
4 | Tomography, X-Ray Computed |
4 | Thiazoles |
4 | Tetrabenazine |
4 | Speech |
4 | Sequence Analysis, DNA |
4 | Regression Analysis |
4 | Reference Values |
4 | Receptors, Dopamine D1 |
4 | Point Mutation |
4 | Piperidines |
4 | Ontario |
4 | Norway |
4 | Nitrophenols |
4 | Neurotoxins |
4 | Monoamine Oxidase Inhibitors |
4 | Microglia |
4 | Mental Status Schedule |
4 | Membrane Potentials |
4 | Lewy Bodies |
4 | Ireland |
4 | Indoles |
4 | Incidence |
4 | Hippocampus |
4 | Heterozygote |
4 | Glucosylceramidase |
4 | Genomics |
4 | Genetic Vectors |
4 | Genetic Therapy |
4 | Gait |
4 | Gait Disorders, Neurologic |
4 | European Continental Ancestry Group |
4 | Enzyme-Linked Immunosorbent Assay |
4 | Electric Stimulation Therapy |
4 | Diagnosis, Differential |
4 | Creatine |
4 | Computer Simulation |
4 | Child, Preschool |
4 | Cerebellum |
4 | Cell Line |
4 | Carrier Proteins |
4 | Benzophenones |
4 | Autophagy |
4 | Apomorphine |
4 | Apolipoproteins E |
4 | Antioxidants |
4 | Aging |
4 | Adaptation, Physiological |
3 | Vesicular Transport Proteins |
3 | Ubiquinone |
3 | Tremor |
3 | Tomography, Emission-Computed, Single-Photon |
3 | Thalamus |
3 | Temporal Lobe |
3 | Sleep Wake Disorders |
3 | Sex Factors |
3 | Serotyping |
3 | Sequence Alignment |
3 | Restless Legs Syndrome |
3 | Receptors, N-Methyl-D-Aspartate |
3 | Receptors, Dopamine D2 |
3 | Radionuclide Imaging |
3 | Protozoan Proteins |
3 | Protein Deglycase DJ-1 |
3 | Population Surveillance |
3 | Polysomnography |
3 | Pigment Epithelium of Eye |
3 | Phylogeny |
3 | Paraquat |
3 | Organ Specificity |
3 | Oncogene Proteins |
3 | Olfaction Disorders |
3 | Odds Ratio |
3 | Neurosurgical Procedures |
3 | Neurologic Examination |
3 | Nervous System Diseases |
3 | Multivariate Analysis |
3 | Movement |
3 | Motor Neuron Disease |
3 | Molecular Chaperones |
3 | Models, Statistical |
3 | Membrane Glycoproteins |
3 | Locomotion |
3 | Inpatients |
3 | Immunoblotting |
3 | Image Processing, Computer-Assisted |
3 | Health Promotion |
3 | Hallucinations |
3 | HEK293 Cells |
3 | Guidelines as Topic |
3 | Genome, Protozoan |
3 | Genes, Dominant |
3 | Gambling |
3 | Fetal Tissue Transplantation |
3 | Family |
3 | Exons |
3 | Enzyme Inhibitors |
3 | Enzyme Activation |
3 | Environmental Exposure |
3 | Electrocardiography |
3 | Educational Status |
3 | Drug Delivery Systems |
3 | Disease Management |
3 | Dependovirus |
3 | DNA |
3 | Cross-Sectional Studies |
3 | Craniocerebral Trauma |
3 | Conserved Sequence |
3 | Computational Biology |
3 | Chromatography, High Pressure Liquid |
3 | Cerebral Cortex |
3 | Central Nervous System |
3 | Cell Transplantation |
3 | Catechol O-Methyltransferase |
3 | Catechol O-Methyltransferase Inhibitors |
3 | Carbidopa |
3 | Brain Tissue Transplantation |
3 | Attention |
3 | Atrophy |
3 | Astrocytes |
3 | Anxiety |
3 | Antipsychotic Agents |
3 | Animals, Newborn |
3 | Amyloid beta-Peptides |
3 | Amino Acids, Diamino |
3 | Alleles |
3 | Accidental Falls |
2 | Zoonoses |
2 | Wolff-Parkinson-White Syndrome |
2 | Vitamin E |
2 | Verbal Learning |
2 | United States Food and Drug Administration |
2 | Ubiquitin |
2 | Transplantation, Heterologous |
2 | Transcriptome |
2 | Transcription Factors |
2 | Tocopherols |
2 | Thiophenes |
2 | Tandem Mass Spectrometry |
2 | Synucleins |
2 | Synteny |
2 | Syndrome |
2 | Synaptic Transmission |
2 | Synapses |
2 | Stuttering |
2 | Streptococcus pneumoniae |
2 | Stereotaxic Techniques |
2 | Statistics as Topic |
2 | Spinocerebellar Degenerations |
2 | Spinal Cord |
2 | Speech Intelligibility |
2 | Solubility |
2 | Software |
2 | Societies, Scientific |
2 | Societies, Medical |
2 | Serial Learning |
2 | Sensitivity and Specificity |
2 | Saskatchewan |
2 | S100 Calcium Binding Protein G |
2 | Rivastigmine |
2 | Reverse Transcriptase Polymerase Chain Reaction |
2 | Retina |
2 | Residence Characteristics |
2 | Reference Standards |
2 | Recurrence |
2 | Recovery of Function |
2 | Recombinant Proteins |
2 | Receptors, Dopamine |
2 | Receptor, Metabotropic Glutamate 5 |
2 | Receptor, Adenosine A2A |
2 | Real-Time Polymerase Chain Reaction |
2 | Rats, Long-Evans |
2 | Radioligand Assay |
2 | Raclopride |
2 | Quinolones |
2 | Proteins |
2 | Protein Conformation |
2 | Protein Binding |
2 | Protein Aggregation, Pathological |
2 | Proprioception |
2 | Problem Solving |
2 | Prions |
2 | Presynaptic Terminals |
2 | Practice Guidelines as Topic |
2 | Population Groups |
2 | Pons |
2 | Polymorphism, Genetic |
2 | Polymerase Chain Reaction |
2 | Pneumococcal Infections |
2 | Placebos |
2 | Placebo Effect |
2 | Pilot Projects |
2 | Phosphorylation |
2 | Phosphoproteins |
2 | Phenylcarbamates |
2 | Perceptual Disorders |
2 | Perception |
2 | Peptide Fragments |
2 | Pedunculopontine Tegmental Nucleus |
2 | Patient Satisfaction |
2 | Patient Participation |
2 | Oxygen |
2 | Oxidopamine |
2 | Nitriles |
2 | Neurturin |
2 | Neuronal Plasticity |
2 | Neuroimaging |
2 | Neurofibrillary Tangles |
2 | Neuroblastoma |
2 | Nerve Net |
2 | Nerve Degeneration |
2 | National Institute of Neurological Disorders and Stroke |
2 | Mutagenesis |
2 | Muscle Rigidity |
2 | Multiple System Atrophy |
2 | Multicenter Studies as Topic |
2 | Motor Skills |
2 | Monocytes |
2 | Models, Molecular |
2 | Mitochondrial Diseases |
2 | Microtubule-Associated Proteins |
2 | Microscopy, Electron |
2 | Microinjections |
2 | Microelectrodes |
2 | Mental Health |
2 | Membrane Transport Proteins |
2 | Medication Adherence |
2 | Manganese |
2 | Macrophages |
2 | Macaca mulatta |
2 | Lipopolysaccharides |
2 | Linear Models |
2 | Kaplan-Meier Estimate |
2 | Isoenzymes |
2 | Intracellular Signaling Peptides and Proteins |
2 | Internet |
2 | Internationality |
2 | Interferon-gamma |
2 | Injections, Intraventricular |
2 | Infant |
2 | Indans |
2 | In Vitro Techniques |
2 | In Situ Hybridization |
2 | Imaging, Three-Dimensional |
2 | Huntington Disease |
2 | Hospitalization |
2 | Homeodomain Proteins |
2 | Hemiplegia |
2 | Health Status |
2 | Health Planning |
2 | Green Fluorescent Proteins |
2 | Glutathione |
2 | Glutamic Acid |
2 | Global Health |
2 | Glial Cell Line-Derived Neurotrophic Factor |
2 | Genetic Testing |
2 | Genetic Markers |
2 | Genetic Loci |
2 | Genetic Linkage |
2 | Gene Expression Regulation, Enzymologic |
2 | Gastrointestinal Diseases |
2 | Frontotemporal Dementia |
2 | Frontal Lobe |
2 | Friedreich Ataxia |
2 | Fluorodeoxyglucose F18 |
2 | Feedback, Sensory |
2 | Excitatory Amino Acid Antagonists |
2 | Evidence-Based Medicine |
2 | Europe |
2 | Eukaryotic Initiation Factor-4G |
2 | Escherichia coli |
2 | Equipment Design |
2 | Epistasis, Genetic |
2 | Environmental Pollution |
2 | Environmental Monitoring |
2 | Endosomes |
2 | Endocytosis |
2 | Ecosystem |
2 | Dyskinesias |
2 | Dysarthria |
2 | Drug Resistance, Multiple, Bacterial |
2 | Drug Interactions |
2 | Drug Industry |
2 | Drug Combinations |
2 | Drug Administration Schedule |
2 | Down-Regulation |
2 | Dopamine Antagonists |
2 | Disruptive, Impulse Control, and Conduct Disorders |
2 | Disorders of Excessive Somnolence |
2 | Diabetes Mellitus |
2 | Datasets as Topic |
2 | Data Interpretation, Statistical |
2 | Data Collection |
2 | DNA-Binding Proteins |
2 | Communicable Diseases |
2 | Communicable Disease Control |
2 | Cold Climate |
2 | Cognitive Dysfunction |
2 | Clinical Trials, Phase II as Topic |
2 | Climate Change |
2 | Cities |
2 | Cholinergic Antagonists |
2 | Cerebrovascular Disorders |
2 | Cerebrovascular Circulation |
2 | Cell Membrane |
2 | Cell Death |
2 | Cell Count |
2 | Cause of Death |
2 | Caudate Nucleus |
2 | Cattle |
2 | Catechols |
2 | Carbon Radioisotopes |
2 | Carbon Isotopes |
2 | Calbindins |
2 | Brain Ischemia |
2 | Brain Injuries |
2 | Brain Chemistry |
2 | Body Mass Index |
2 | Blood-Brain Barrier |
2 | Biomedical Research |
2 | Biomechanical Phenomena |
2 | Biological Transport |
2 | Benzoxazoles |
2 | Base Sequence |
2 | Axonal Transport |
2 | Awareness |
2 | Autoradiography |
2 | Autonomic Nervous System Diseases |
2 | Australia |
2 | Aripiprazole |
2 | Apoptosis |
2 | Aphasia |
2 | Antidepressive Agents |
2 | Anti-Dyskinesia Agents |
2 | Animal Experimentation |
2 | Amino Acid Substitution |
2 | Alaska |
2 | Air Pollutants |
2 | Adenosine |
2 | Acute Disease |
1 | trans-Golgi Network |
1 | p38 Mitogen-Activated Protein Kinases |
1 | X-Ray Absorption Spectroscopy |
1 | Workplace |
1 | Wireless Technology |
1 | Weight-Bearing |
1 | Waterborne Diseases |
1 | Water |
1 | Walking |
1 | Vomiting |